Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Michael Zenni

Urology Evansville, IN Medical Doctor

NPI 1790774404 CMS profile 585038

920 S Hebron Ave, Evansville, IN 47714

Open in the dashboard

General payments

$258

20 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Michael Zenni of Evansville, IN is reported in the CMS Open Payments database as having received $258 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 16th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $258 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Zenni
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Michael Zenni were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Michael Zenni Urology median Middle half National median
2019 $258 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program year 2019
  1. Astellas Pharma US Inc $137 12 payments
  2. Boston Scientific Corporation $40 3 payments
  3. Blue Earth Diagnostics Limited $26 1 payment
  4. Amgen Inc. $16 1 payment
  5. Medtronic USA, Inc. $14 1 payment
  6. AbbVie, Inc. $13 1 payment
  7. Coloplast Corp $11 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $258 20 payments
Products named General payments · program year 2019
  1. MYRBETRIQ $97 8 payments
  2. XTANDI $87 8 payments
  3. Axumin $26 1 payment
  4. Prolia $16 1 payment
  5. GENERAL FEMALE SUI $14 1 payment
  6. INTERSTIM $14 1 payment
  7. LITHOVUE $14 1 payment
  8. LUPRON DEPOT $13 1 payment
  9. General Therapies $13 1 payment
  10. SPEEDICATH $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,391

Median for Urology: 1,053

Drug cost

$90,861

Median for Urology: $101,464

Branded share of claims

11.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 77 $72,850
Tamsulosin Hcl Generic 521 $6,580
Finasteride Generic 454 $5,160
Solifenacin Succinate Generic 32 $2,106
Dutasteride Generic 22 $860
Estradiol Generic 15 $653
Cephalexin Generic 54 $631
Oxybutynin Chloride Generic 20 $628
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 57 $440
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 12 $298

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$126,213

Of which drugs: $14,702

Medicare patients

598

Average age 75

Services billed

1,809

109 women, 489 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 35%
Diabetes 31%
Chronic kidney disease 27%
Atrial fibrillation 23%
Cancer 22%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 13 105 $14,700

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record